Research Institute for Biological Safety Problems   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Gvardeyskiy Kazakhstan (1958)

Organization Overview

First Clinical Trial
2013
NCT03017378
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Research Institute for Biological Safety Problems

Active Ingredients

Drugs in Phase 3 Trials (2)

inactivated influenza vaccine (2 trials)

qazcovid-in (3 trials)

Drugs in Phase 2 Trials (2)

split virion influenza vaccine (1 trial)

vaxigrip (1 trial)

Drugs in Phase 1 Trials (2)

tb/flu-01l (1 trial)

Tuberculin, Purified Protein Derivative (Tubersol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 3)

Influenza, Human (Phase 3)

Severe Acute Respiratory Syndrome (Phase 3)

Tuberculosis (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 6